833-05-6

Basic information

• Product Name: 1-(5-Chloro-1H-indol-3-yl)-2-Methylpropan-2-aMine
• Synonyms: 1-(5-Chloro-1H-indol-3-yl)-2-Methylpropan-2-aMine
• CAS NO: 833-05-6
• Molecular Formula: C₁₂H₁₅ClN₂
• Molecular Weight: 222.7139
• Mol File: 833-05-6.mol
• Article Data: 1

Chemical Properties

• Melting Point: 156.0-157.5 °C
• Boiling Point: 380.5°Cat760mmHg
• Flash Point: 183.9°C
• Appearance: /
• Density: 1.214g/cm³
• Vapor Pressure: 5.44E-06mmHg at 25°C
• Refractive Index: 1.635
• PKA: 16.61±0.30(Predicted)
• CAS DataBase Reference: 1-(5-Chloro-1H-indol-3-yl)-2-Methylpropan-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(5-Chloro-1H-indol-3-yl)-2-Methylpropan-2-aMine(833-05-6)
• EPA Substance Registry System: 1-(5-Chloro-1H-indol-3-yl)-2-Methylpropan-2-aMine(833-05-6)

Safety Data

• Hazardous Substances Data: 833-05-6(Hazardous Substances Data)

Usage

General Description

1-(5-Chloro-1H-indol-3-yl)-2-Methylpropan-2-aMine is a chemical compound that belongs to the class of alpha-aminos. It is known for its potential biological activity and is often used in pharmaceutical and research applications. 1-(5-Chloro-1H-indol-3-yl)-2-Methylpropan-2-aMine has a molecular formula of C13H14ClN and a molecular weight of 231.71 g/mol. It is characterized by its 5-chloro-1H-indol-3-yl and 2-methylpropan-2-amine functional groups. The compound may have potential therapeutic effects, although further research is needed to better understand its properties and applications.

InChI:InChI=1/C12H15ClN2/c1-12(2,14)6-8-7-15-11-4-3-9(13)5-10(8)11/h3-5,7,15H,6,14H2,1-2H3

Upstream product

• 4771-70-4 5-chloro-3-(2-methyl-2-nitropropyl)-1H-indole 

Downstream Products

• 169505-93-5 RS 17053 
• 1237817-77-4 [2-(1H-indol-3-yl)-1,1-dimethylethyl]{2-[2-(tetrahydrofur-2-ylmethyloxy)phenoxy]ethyl}amine hydrochloride 

Relevant articles and documents

N-ARYLOXYALKYL TRYPTAMINE ALPHA1-ADRENERGIC RECEPTOR ANTAGONISTS

The present invention relates to novel N-aryloxyalkyl tryptamine . alpha. 1-adrenergic receptor antagonists of the formula I: STR1 in which n is 2, 3 or 4; q is 1, 2 or 3; t is 0, 1, 2 or 3; z is 0, 1, 2 or 3; each R 1 and R 2 are independently hydroxy, halogen, cyano, (C 1-8)alkyl, (C 1-8)alkyloxy or trifluoromethyl; and R 2 is hydrogen, (C 1-4)alkyl, fluoro(C 1-4)alkyl, difluoro(C 1-4) alkyl, trifluoro(C 1-4)alkyl, (C 1-4) alkyloxy(C 1-4)alkyl, oxo(C 1-4)alkyl, (C 1-8)cycloalkyl, (C. sub.1-8)cycloalkylmethyl or allyl or phenyl(C 1-4)alkyl or heterocyclo(C 1-8)alkyl (optionally substituted with one to two substituents independently selected from (C 1-4)alkyl, (C 1-4) alkyloxy, trifluoromethyl and halogen); R. sup.3 and R 4 are independently hydrogen, (C 1-4) alkyl, (C 1-8)cycloalkyl, (C 1-8)cycloalkylmethyl or allyl; and R. sup. 5 is hydrogen, (C 1-4)alkyl, (C 1-8)cycloalkyl, (C 1-8) cycloalkylmethyl, allyl, (C 1-4) alkylsulfonyl and aminocarbonyl; with the proviso that when n is 2, t is 0, q is 1, z is 0, 1 or 2, R 5 is hydrogen and R 6 is hydroxy or (C 1-8)alkyloxy then at least one of R 3 and R 4 is not hydrogen; and the pharmaceutically acceptable salts, individual isomers, and mixtures of isomers thereof; their uses as therapeutic agents and the methods of their making.